Please assess the completion status of the following clinical trial:

Trial Title: Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients without evidence of any clinically apparent arrhythmia recurrence during at least six months after last catheter ablation of AF.~* Willing and able to provide informed consent~Exclusion Criteria:~* Patients who do not meet all of the above listed inclusion criteria.~* Patients with significant valvular heart disease or mechanical valve.~* Patients with hypertrophic cardiomyopathy.~* Patients with chronic renal impairment with creatinine clearance rate of \< 30 mg/dl.~* Patients with contraindication to long-term OAC.~* Patients who had a stroke within one year prior to enrolment.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Antiplatelet therapy (Type: EXPERIMENTAL): acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA
- Low-dose OAC therapy (Type: EXPERIMENTAL): Edoxaban of 30mg (Reduced dose of 15mg if body weight \< 60kg, CCr\< 50 ml/min, concomittant use of P-gp)
- Standard-dose OAC therapy (Type: ACTIVE_COMPARATOR): Edoxaban of 60mg (Reduced dose of 30mg if body weight \< 60kg, CCr\< 50 ml/min, concomittant use of P-gp)

Based on this trial design, predict the completion outcome and termination type (if applicable).